Device Trial Radar · NCT00387803
Safety and Effectiveness of Cardiac Resynchronization Therapy With Defibrillation
Last checked: Nov 20, 2026Latest source record: Jan 25, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
581
Actual
Start
Feb 1998
Primary completion
Not stated
Study completion Aug 2001
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Oct 13, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine if cardiac resynchronization therapy when combined with defibrillation is safe and effective in the treatment of symptomatic heart failure.
Conditions
- Heart Failure, Congestive
- Ventricular Fibrillation
- Tachycardia, Ventricular
Interventions
Cardiac Resynchronization Therapy with DefibrillationDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of all-cause mortality, heart failure hospitalization, and ventricular tachyarrhythmia
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Multiple locations
Saint Paul, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.